Nirsevimab for Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Infants: A Systematic Review of Randomized Controlled Trials

Authors

  • Dwi Novilolita Fakultas Kedokteran Universitas Prima Nusantara Author
  • Vistaria Furkano Universitas Prima Nusantara Bukittinggi Author
  • Sakinah Shadrina Universitas Prima Nusantara Bukittinggi Author

DOI:

https://doi.org/10.35730/y3teyv85

Keywords:

Nirsevimab, respiratory syncytial virus, infants, monoclonal antibody

Abstract

Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) and hospitalization in infants. Nirsevimab is a long-acting monoclonal antibody given as a single dose. This systematic review summarizes its efficacy and safety in randomized controlled trials (RCTs).

Methods: RCTs of nirsevimab in infants, reporting medically attended RSV LRTI or hospitalization, were eligible. Data were extracted and synthesized without meta-analysis following the SWiM reporting guideline, with qualitative risk-of-bias appraisal using RoB 2 domains.

Findings: Three RCTs (a phase 2b trial, MELODY, and HARMONIE; 11,001 randomized infants) were included. Efficacy against medically attended RSV LRTI was 70.1% (95% CI 52.3–81.2) in the phase 2b trial, 74.5% (95% CI 49.6–87.1) in MELODY, and 83.2% (95% CI 67.8–92.0) against RSV LRTI hospitalization in HARMONIE. Serious adverse events were similar between groups in the placebo-controlled trials.

Conclusion: Nirsevimab reduced RSV LRTI in infants across three trials, with an acceptable short-term safety profile. Data from Indonesia and tropical settings were not found.

Downloads

Published

2026-09-30